| OAF0302 | Missing: meaningful trans inclusion in HIV national strategic plans in Eastern and Southern Africa | Oral abstract session with live Q&A | Accountability on the HIV response |
| OAF0303 | Disability inclusion in the national response to HIV/AIDS in Nigeria: an analysis of the national strategic plan and framework | Oral abstract session with live Q&A | Accountability on the HIV response |
| OAF0304 | Meaningful inclusion and effective participation of people who use drugs in shaping access to HIV/AIDS services: implications of a donor funding policies in 11 Latin American countries | Oral abstract session with live Q&A | Laws, policies and practices impacting access to HIV testing, prevention, treatment, care and support |
| OAF0305 | Towards more inclusive and feminist approaches in HIV programming evaluations: transforming principles into practice | Oral abstract session with live Q&A | Foregrounding accountability within the HIV response |
| OAF0402 | Bad blood: why blood donations by people living with HIV should not be a crime | Oral abstract session with live Q&A | Laws and policies on HIV transmission, exposure, and non-disclosure |
| OAF0403 | Measuring potential impacts of parental consent laws on adolescent HIV testing globally: multinational insights from 51 population-based surveys | Oral abstract session with live Q&A | Laws, policies and practices impacting access to HIV testing, prevention, treatment, care and support |
| OAF0404 | Ending inequalities in access to justice: scaling up and sustaining judicial sensitization across sub-Saharan Africa | Oral abstract session with live Q&A | Legal advocacy tools and strategies |
| OAF0405 | The race to end AIDS: Ghana's prospects in light of a proposed anti-LGBTQ bill | Oral abstract session with live Q&A | Challenging criminalization of sexuality, gender identity and bodily autonomy as a driver of HIV programme exclusion |
| OALBA0102 | Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial | Oral abstract session with live Q&A | Humoral immunity (including broadly neutralizing antibodies), Antibodies and B cells |
| OALBA0103 | Flt3 agonist enhances immunogenicity of arenavirus-vector based vaccines in macaques | Oral abstract session with live Q&A | Novel vectors, adjuvants and strategies |